Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
How would you approach a localized but unresectable adenoid cystic carcinoma of the distal trachea?
Answer from: Radiation Oncologist at Academic Institution
Curative intent RT
Comments
Radiation Oncologist at University of Cincinnati Cancer Center
Can you describe your treatment volumes?
11395
Sign in or Register to read more
17928
Related Questions
Do more fractionated regimens reduce severe toxicity over SBRT in patients with ILD and early-stage NSCLC?
What radiation treatment volume would you include in chemoradiation given for perihilar lymph node recurrence after surgical resection and mediastinal lymph node dissection for NSCLC?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
Would you offer empiric lung SBRT for two growing FDG-avid lung lesions in a patient with severe COPD on oxygen?
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
What dose contraints do use for the pulmonary artery and vein when treating with a lung lesion with SBRT?
Do you use an LAD constraint in the setting of BID thoracic radiation for SCLC?
For NSCLC patients treated with neoadjuvant chemoimmunotherapy and surgery with ypN2 disease, what factors would cause you to recommend PORT?
Would you offer lung SBRT in a patient with Pulmonary Langerhans Cell Histiocytosis (PLCH)?
Given the findings of SUNSET, demonstrating 60 Gy in 8 fractions to be a safe and effective regimen for ultracentral lesions, in what situations would you elect to use a 10 fraction hypofractionated regimen?
Can you describe your treatment volumes?